Keros Therapeutics (KROS) EBITDA Margin (QoQ) (2019 - 2025)
Powered by 
Analysis
Keros Therapeutics (KROS) EBITDA Margin (QoQ) (2019 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Keros Therapeutics | 220.97 Mn | -36.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -749,473.00 |
| Sep 30, 2025 | 11,129.00 |
| Jun 30, 2025 | -29,113.00 |
| Mar 31, 2025 | 182,260.00 |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 12.12 Mn |
| Jun 30, 2024 | -7.79 Mn |
| Mar 31, 2024 | -2.59 Mn |
| Dec 31, 2023 | 50.85 Mn |
| Mar 31, 2022 | -10,970.00 |
| Dec 31, 2019 | -1,608.00 |
| Sep 30, 2019 | 1,300.00 |
| Jun 30, 2019 | 828.00 |